Mogamulizumab

From Wikipedia, the free encyclopedia
Mogamulizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CCR4
Clinical data
Trade names Poteligeo
Legal status ?
Routes IV
Identifiers
CAS number 1159266-37-1 N
ATC code None
Chemical data
Formula C6520H10072N1736O2020S42 
Mol. mass 146.44 kDa
 N (what is this?)  (verify)

Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.[1]

Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd.[2] It has also been licensed to Amgen for development as a therapy for Asthma.[3]

References

  1. ↑ Subramaniam, J; Whiteside G, McKeage K, Croxtall J (18 June 2012). "Mogamulizumab: First Global Approval". Drugs 72 (9): 1293–1298. doi:10.2165/11631090-000000000-00000. Retrieved 10 September 2012. 
  2. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab". American Medical Association. 
  3. ↑ "Kyowa Hakko Kirin R&D Pipeline". Kyowa Hakko Kirin. Retrieved 10 September 2012. 
Monoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.